华蟾素胶囊联合美施康定对肺腺癌EGFR突变骨转移癌痛患者的临床疗效的观察

Clinical Observation on the Efficacy of Cinobufagin Capsules Combined with MS Contin in Patients with Lung Adenocarcinoma Harboring EGFR Mutation Complicated with Bone Metastasis and Cancer Pain

摘要: 目的：探讨华蟾素胶囊联合美施康定对肺腺癌表皮生长因子(EGFR)突变骨转移癌痛患者的临床疗效，分析其对镇痛效果、睡眠质量、生存质量及炎性因子变化的影响。方法：选取我院2023年~2025年在院肺腺癌EGFR突变骨转移癌痛患者106例，随机分两组，每组53例。对照组单用美施康定治疗，实验组选择华蟾素胶囊联合美施康定治疗。结果：与对照组相比，实验组的镇痛效果总有效率显著高于对照组(P < 0.05)；实验组睡眠质量和生存质量改善情况优于对照组(P < 0.05)；实验组人均美施康定口服剂量较对照组显著减少(P < 0.05)；实验组对比对照组副作用显著减少(P < 0.05)；治疗后，两组患者的IL-6、TNF-α均有所下降，但实验组下降更为明显(P < 0.05)。结论：华蟾素胶囊联合美施康定治疗肺腺癌EGFR突变骨转移癌痛患者的镇痛效果相较于单用美施康定治疗患者更好，患者生存质量更高，睡眠质量更高，服用阿片类药物剂量减少，副作用更少，IL-6、TNF-α的炎性因子水平降低，具有较好的临床应用价值。

Abstract: Objective: To investigate the clinical efficacy of Cinobufagin Capsules combined with MS Contin in patients with lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation and bone metastasis-related cancer pain, and to analyze its effects on analgesic effect, sleep quality, quality of life and inflammatory factors. Methods: A total of 106 patients with lung adenocarcinoma with EGFR mutation and bone metastasis-induced cancer pain admitted to our hospital from 2023 to 2025 were randomly divided into two groups, with 53 cases in each group. The control group was treated with MS Contin alone, and the experimental group was treated with Cinobufagin Capsules combined with MS Contin. Results: Compared with the control group, the total effective rate of analgesia in the experimental group was significantly higher (P < 0.05). The improvements in sleep quality and quality of life in the experimental group were better than those in the control group (P < 0.05). The mean oral dosage of MS Contin in the experimental group was significantly lower than that in the control group (P < 0.05). Adverse reactions in the experimental group were significantly fewer than those in the control group (P < 0.05). After treatment, IL-6 and TNF-α levels were decreased in both groups, and the decrease was more significant in the experimental group (P < 0.05). Conclusion: Compared with MS Contin alone, Cinobufagin Capsules combined with MS Contin has a better analgesic effect in patients with lung adenocarcinoma with EGFR mutation and bone metastasis-related cancer pain. It can improve quality of life and sleep quality, reduce opioid dosage and adverse reactions, and decrease the levels of inflammatory factors IL-6 and TNF-α, showing good clinical application value.